Phase II and Pharmacodynamic Study of the Farnesyltransferase Inhibitor R115777 as Initial Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
- 1 April 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (7) , 1301-1306
- https://doi.org/10.1200/jco.2003.08.040
Abstract
Purpose: R115777 is a selective nonpeptidomimetic inhibitor of farnesyltransferase (FTase), one of several enzymes responsible for posttranslational modification that is required for the function o...Keywords
This publication has 18 references indexed in Scilit:
- Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast CancerJournal of Clinical Oncology, 2003
- Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studiesOncogene, 2000
- Pancreatic cancerCurrent Treatment Options in Oncology, 2000
- Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell linesOncogene, 1997
- Six Hundred Fifty Consecutive Pancreaticoduodenectomies in the 1990sAnnals of Surgery, 1997
- High frequency of Ki‐ras codon 12 mutations in pancreatic adenocarcinomasInternational Journal of Cancer, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958